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Doxorubicin (DOX) is an effective anti-neoplastic agent for the treatment of 
various tumors and carcinomas. However, its clinical applications are limited as it 
exerts significant cardiotoxicities, which are dose-dependent, cumulative and 
irreversible. 
. 一 -
Efforts on developing potential cardioprotective drugs have been put to 
minimize this side effect of DOX. Our hypothesis is that thrombopoietin (TPO), a 
hematopoietic/megakaryocytopoietic growth factor, protects against DOX-induced 
cardiac injuries through the anti-apoptotic mechanisms. In this study, we aimed (1) To 
evaluate the effects of TPO on DOX-induced cardiotoxicity in the in vitro models of 
cardiomyocytes, rat H9C2 cell line and primary, neonatal rat ventricular beating 
myocytes. (2) To establish an in vivo mouse model of DOX-induced cardiac damage 
i 
and to study the effects of TPO on the in vivo model. (3) To investigate the 
mechanism of TPO on myocardial protection in the in vitro model of H9C2 cells and 
in vivo model. 
� Our results demonstrated that DOX (5 |ig/mL, 24 hours) significantly reduced 
H9C2 cell viability by 26.2 % ± 1.1 % (n = 4，p < 0.001)，and TPO recovered their 
viability to 85.6 % 土 4.4 % (100 ng/mL, p = 0.016) at a dose-responsive manner. 
DOX (0.58 |ig/mL) also reduced the beating rates of primary neonatal beating 
cardiomycoytes to 15.2 % 土 16.9 % at 48 hours, when comparing with the control (n 
=10，p < 0.001). Administration of TPO (100 ng/mL) significantly increased the 
beating rates of DOX-treated cells to 47.8 % 土 22.9 % at 48 hours (p = 0.002). In the 
mouse model, we observed decrease in heart rate (HR), fraction shortening (FS) and 
cardiac output (CO) measured by echocardiography in DOX-treated mice (20 mg/Kg, 
i.p.，Day 0). Treatment with TPO (12.5 ng/Kg, i.p.，Days -1，+1 and +3) significantly 
increased all the three parameters. Effects of TPO were further confirmed by the heart 
histology with reduced cardiomyopathy score, when compared with DOX-treated 
mice. In addition, we demonstrated that TPO reduced DOX-induced apoptosis of 
H9C2 cells and mouse hearts as demonstrated by assays of Annexin V，active 
Caspase-3 and mitochondrial membrane potential, and TUNEL assay respectively. 
ii 
We provided the first evidence that TPO is a potential cardioprotective agent 
against DOX-induced myocardial damages. We propose to further develop TPO in 















硏究結果發現 DOX (5 ng/mL，24 hours)顯著降低 26.2 % ± 1.1 % H9C2 
細胞存活率（n = 4 ’ P < 0.001)，但細胞活性以劑量反應方式在100 ng/mL的 
TPO 下恢復到 85.6 % 土 4.4 % ( P = 0.016)�同時 DOX (0.58 i^g/mL ’ 48 hours ) 
降低原始心肌細胞搏動率至15.2 % 土 16.9 % (n = 10 ’ p < 0.001) ’而TPO (100 
iv 
ng/mL，48 hours)顯著提高心肌細胞搏動率到47.8 % ± 22.9 % (p = 0 .002)�透 
過超聲心動圖檢測，我們發現在DOX弓丨起心臟損傷的小鼠（20 mg/Kg，腹腔注 
射，DayO)，其心率（HR)�縮短分數（FS)和心輸出量（CO)均下降。以TPO 
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Ch 1 General Introduction 
C H A P T E R 1 
General Introduction 
SECTION 1.1 Background and Clinical Application of 
Anthracyclines 
The first report on the anti-neoplastic effect of anthracyclines was published in 1963. 
Anthracyclines are glucosidic antibiotics isolated from pigment-producing Streptomyces 
peiicetius. Daunorbicin (Figure 1.1 A) and its analogue Doxorubicin (DOX, also known as 
adriamycin, Figure LIB) were the first 2 isolated anthracyclines. Since the discovery, 
anthracyclines become one of the most important agent against a broad spectrum of 
cancer because of their high anti-tumour potency (Weiss, 1992; Hortobagyi, 1997; Zucchi 
and Danesi, 2003; Minotti et al.，2004). Anthracyclines are widely utilized for both 
paediatric and adult patients and most patients under systemic chemotherapy receive 
anthracyclines during the course of treatment (Weiss, 1992; Hortobagyi, 1997). Due to 
the development of anthracycline as well as other treatment improvement, the survival 
rate of cancer patients have been raised form 30 % in 1960s to 70 % currently, especially 
1 
Ch 1 General Introduction 
among paediatric patients (Bleyer, 1990; Gatta et al., 2002; Wouters et al, 2005). 
Because of a single hydroxyl group difference in chemical structure, DOX exerts a 
greater extent of anti-tumour activity and a better therapeutic index than daimorbicin (Di 
et al., 1969; Weiss, 1992; Booser and Hortobagyi, 1994; Minotti et al” 2004). Today, 
DOX still remains to be the first-line anti-tumour agent, either used as a single agent or in 
combination with other treatment regimens, in the treatment of various haematopoietic 
malignancies such as leukemias and solid tumors including breast cancers, ovarian 
cancers, lung cancers, lymphomas and sarcomas (Booser and Hortobagyi, 1994; 
Hortobagyi, 1997; Singal et al., 2000). However, there are still some cancers that are not 
responsive to DOX treatment, such as colon cancers (Davis and Davis, 1979; Singal et al., 
2000). 
The anti-tumour activity of DOX is largely attributed to irreversible DNA injury of 
the cancer cells. Previous studies proposed that the anti-tumour effects of DOX may be 
mediated by increased oxidative stress. However, recent reports suggested that these 
effects may caused by the non-free radical dependent mechanisms, including the 
intercalation of DOX between adjacent deoxyribonucleic acid (DNA) base pairs, 
inhibition of topoisomerase II and DOX-iron complex binding to DNA (Booser and 
2 
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Hortobagyi, 1994; Gewirtz, 1999; Horenstein et ai, 2000; larussi et aL, 2001，Singal et 
a/.,2001). In the process of intercalation, DOX binds to DNA and inserts its multi-ring 
structure between adjacent base pairs. This process causes deformation of DNA by 
inhibiting the replication and transcription of DNA. DNA deformation stabilizes the 
normally reversible topoisomerase II-DNA complex, resulting in the production of 
double-strand DNA breaks (Meriwether and Bachur, 1972; Reinert, 1983; Abraham et al., 
1996; Hortobagyi, 1997; larussi et aL, 2001). 
SECTION 1.2 DOX-induced Cardiotoxicity 
Despite its highly effective anti-neoplastic activity, DOX is associated with adverse 
cardiotoxicities which are dose-related, cumulative and essentially irreversible. Besides 
the common side effects of nausea, vomiting, mucositis, myelosuppression and alopecia 
(Speyer and Wasserheit, 1998), DOX-induced cardiotoxicity results in increased risk of 
development of cardiomyopathy and ultimately congestive heart failure (Minow et al., 
1975; Bristow et al., 1978a; Kalyanaraman et al., 2002). 
This life threatening cardiotoxicity limits the use of DOX in the clinical practice, as 
the risk of cardiomyopathy have been observed to increase significantly in patient 
3 
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receiving dose of DOX > 550 m g W . Different mechanisms of DOX have been 
suggested in its anti-cancer effects and its cardiotoxicities (Kluza et al., 2004; Wang et al., 
2004; Yeh et al., 2004). Two distant types of DOX-induced cardiotoxicities have been 
described as acute and chronic cardiotoxicities. 
1.2.1 Types of Cardiotoxicity 
1.2.1.1 Acute Cardiotoxicity 
Acute toxicity is dose-related and partially related to the peak plasma concentration 
of DOX (Legha et al., 1987; Speth et al” 1988). These acute effects usually occur during 
or within minutes or hours after DOX administration and are characterized by 
hypotension, tachycardia and various arrhythmias, which are transient, reversible and/or 
clinically manageable (Rinehart et al, 1974; Singal et al,, 1987; Hershko et al” 1996; 
Singal et al., 1997). An acute pericarditis-myocarditis syndrome or acute left ventricular 
failure has also been described (Bristow et al., 1978a; Shan et al., 1996; Speyer and 
Wasserheit, 1998). Electrocardiographic changes are observed include ST segment 
depression, T-wave changes, reduced QRS voltage and prolongation of the QT interval 
(Shan et aL, 1996). 
4 
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1.2.1.2 Chronic Cardiotoxcity 
In contrast to acute cardiotoxicity, chronic cardiotoxicity often develop within a year 
after the completion of treatment and can persist years to decades after the therapy 
(Singal et al.’ 1987; Singal et al, 1997; Zucchi and Danesi, 2003). The chronic toxic 
effects of DOX are characterized by electrophsiologic changes, progressive impairment 
of systolic and diastolic function, changes in exercise-stress capacity, arrhythmias, and 
increased serum levels of creatine phosphokinase and other cytoplasmic enzymes 
(Gottdiener et al., 1981; Lee et al, 1987; Hershko et al., 1996; Schimmel et al., 2004). 
This chronic cardiotoxicity are cumulative, dose-dependent and irreversible, which 
progress to the development of cardiomyopathy and ultimately congestive heart failure 
(Singal et al., 2001). 
The risk of the development of congestive heart failure depends on the cumulative 
dose of DOX (Shan et al,, 1996; Zucchi and Danesi, 2003). Patients receiving less than 
400 mg/m^ DOX have less than 3 % of developing congestive heart failure. The risk rises 
to 18 % at 700 mg/m^ and reaches around 50 % at 1000 mg/m^ (Doroshow, 1991). 
Therefore, in the clinical setting, a lifetime dose of 450-550 mg/m is considered to be the 
upper limit in order to minimize the risk of development of congestive heart failure 
5 
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(Lipshultz et al” 2005; Wouters et aL, 2005). 
1.2.2 Subcellular Effects ofDOX 
1.2.2.1 Ultrastructural Lesions 
The myocardial lesions are characterized by myofibrillar degeneration, cytoplasmic 
vacuolization, vacuolar degeneration of the sarcoplasmic reticulum (SR), swelling of 
cardiac mitochondria with disorganization of the cistae, accumulation of lipids, increased 
number of lysosomes, interstitial edema and focal myocytolysis (Lefrak et al., 1973; 
Jaenke and Fajardo, 1977; Bristow et al,, 1978b; Singal et aL, 1987; Olson and Mushlin, 
1990； Singal et aL, 2001). In the area of myocardial degeneration, various structural 
abnormalities have been observed, including multiple vacuoles, myocardial cell swelling, 
intracellular inclusion bodies occurrence and myofibrillar pattern disorganization or 
disappearance (Lenaz and Page, 1976). The earliest changes of ultrastmcture are involved 
in the SR and mitochondria (Olson and Mushlin, 1990). A previous study reported that 
mice treated with a single dose of DOX presented myocardial lesions of SR and 
mitochondria after 14 hours of administration (Lambertenghi-Deliliers et al” 1976). The 
lesions were found to progress over 3-5 days with observation of cumulating in valcuolar 
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degeneration of SR, swelling and disruption of mitochondria, and disorganization of 
myofibrils. Endomyocardial biopsy samples from patients also showed similar lesions 
after 4 and 24 hours of an initial dose of 30-60 mg/m^ of DOX (Unverferth et al.，1981). 
These ultrastmctural changes have been found in different animal models, including 
rabbits (Jaenke, 1974; Olson et al., 1974)， mice (Rosenoff et al., 1975; 
Lambertenghi-Deliliers et al, 1976) and rats (Weinberg and Singal, 1987; Singal et al, 
1995). 
1.2.2.2 Effects on Mitochondrial Functions 
Mitochondrial functions are impaired by the administration of DOX. The major 
defects are the accumulation of calcium ion (Ca^ "^ ) and inhibition of adenosine 
triphosphate (ATP) synthesis (Singal and Pierce, 1986; Olson and Mushlin, 1990; 
Hershko et al, 1996). In an experiment on isolated rat heart preparations of 60 minutes 
exposure of DOX, ATP and creatine phosphate synthesis were decreased by 25 % 
(Ohliara et al., 1981). DOX also directly inhibits the transporting elements in respiratory 
chain and the substrate translocator proteins (Bachmann et al.’ 1987; Bianchi et al., 1987; 
Wallace, 2003). Besides, the inhibition of mitochondrial respiratory enzymes has been 
observed (Cargill et al., 1974; Gosalvez et al., 1974; Lenaz and Page, 1976). Previous 
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Study showed that moderate uncoupling of oxidative phosphorylation was found in 
rabbits treated with DOX (0.8 mg/Kg) daily for 7-15 days and reversible of these changes 
were observed in 2 weeks after the cessation of treatment (Ferrero et al., 1976). 
1.2.2.3 Effects on Sarcoplasmic Reticulum (SR) Functions 
The functions of SR are to store, sequester and release myocardial Ca�.，which 
determines both systolic (active) and diastolic (passive) cardiac functions. The two 
primary site of SR function are longitudinal tubules and terminal cistemae. Longitudinal 
tubules are responsible for sequestration and transport of Ca^ "^  to terminal cistemae. 
Terminal cisterane stores Ca^^ for release to the contractile apparatus through the Ca^ "^  
一一 
release channels (Olson and Mushlin, 1990; Hershko et al, 1996). DOX does not inhibit 
the sequestration of Ca^^ into longitudinal tubules, but it triggers the opening of the 
calcium release channels of terminal cistemae, and thus affecting the contractile function 
(Abramson and Salama，1988; Kim et al., 1989). 
SECTION 1.3 Mechanisms of DOX-induced Cardiotoxicity 
Although the precise mechanisms of DOX-induced cardiotoxicity have not yet been 
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elucidated, they are believed to be different from those responsible for anti-neoplastic 
effectiveness as observed in the preclinical and clinical data (Arola et al.’ 2000; larussi et 
al., 2001; Zucchi and Danesi, 2003). 
Several mechanisms have been proposed including formation of free radical, 
disruption of calcium homeostasis, mitochondrial dysfunction, alternations of myocardial 
adrenergic function, interference with phospholipid distribution and metabolism, 
inhibition of enzymes and proteins, modulation of cardiac muscle gene expression and 
induction of apoptosis (Olson and Mushlin, 1990; Kumar et al, 1999; Arola et al” 2000; 
Liu et al., 2002; Burke et al., 2003; Zucchi and Danesi, 2003). Cardiotoxicity induced by 
DOX may be multifactorial and complex, however, most of the evidences support the 
- 一 -
mechanism of free radical formation (Zucchi and Danesi, 2003). 
1.3.1 Formation of Free Radicals 
Free radicals, also known as reactive oxygen species (ROS), are molecules or atoms 
consisting of one or more unpaired electrons in their valence, such as superoxide anion 
(02-') or hydroxyl radical (-OH) (Olson et al., 1981; Horenstein et ai, 2000; Singal et al., 
2000). Due to the existence of unpaired electrons, free radicals are highly reactive and 
9 
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readily interact with macromolecules, including enzymes and other membrane cytosol 
component (Olson et al., 1981; Wouters et al” 2005). 
1.3.1.1 Generation of Free Radicals by DOX 
Free radical formation can be explained by the chemical structure of DOX, the 
quinone ring C (Figure LIB) is potent to form semiquinone free radical. One-electron 
reduction of ring C by flavin-dependent reductases (i.e. Nicotinamide adenine 
dinucleotide phosphate (NAPDH) cytochrome P-450 reductase, Nicotinamide adenine 
dinucleotide (NADH) dehydrogenase and xanthine oxidase) results in the formation of a 
free-radical semiquinone. Under aerobic conditions, the semiquinone transfers its 
. 产 -
unpaired electron to oxygen generating superoxide anion, and the quinone form of DOX 
is regenerated. These sequential reactions are known as 'redox-cycling' (Figure 1.2A) 
(Keizer et al., 1990; Singal et al” 2000). The superoxide anion can be catalyzed by 
superoxide dismutase to form molecular oxygen (O2) and hydrogen peroxide (H2O2) or 
react with polyunsaturated fatty acids to form lipid peroxide (ROOH). H2O2 and ROOH 
can subsequently decompose to OH- and peroxide radical (ROO.) respectively. These free 
radicals, including H2O2, ROOH and O2: can cause damage to cell membrane, 
macromolecules and myocardial injury (Horenstein et al., 2000; larussi et al., 2001). 
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Free radicals can also be formed through non-enzymatic pathway by the reaction of 
DOX and iron (Figure 1.2B) (Olson and Mushlin, 1990; Horenstein et al, 2000; Wouters 
et al., 2005). Ferric ion (Fe^ "^ ) reacts with the ketone and hydroxyl groups of DOX and 
form D0X-Fe2+ complex by an electron flow to iron. DOX-Fe^^ complex reduce O2 to 
superoxide anion, after which an electron flows from ferrous ion (Fe^ "^ ) to DOX, 
generating the new DOX-Fe^"^ complex. DOX-Fe^"^ aldehyde is formed by the 
rearrangement of DOX-Fe^"^ complex and oxidized to form DOX-Fe^"^ aldehyde as 
another O2 is reduced to superoxide anion. Superoxide anion may react to O2 and H2O2 
by superoxide dismutase and react to the lipid of cell membrane, forming lipid peroxides, 
which can form alkoxy-radical (RO.) and peroxyl-radical (ROO.). These free radicals, 
including RO.，ROO and O2 " cause injury to the cellular and mitochondrial membranes, 
resulting in cardiomyocyte death (Olson and Mushlin, 1990; Horenstein et al” 2000). 
Although very little free iron is available in myocytes, the source of iron (Fe�.）is 
suggested by ferrtin-bound Fe�"*"，since recent studies have shown that DOX can release 
iron from ferritin, suggesting that bound iron may contribute to free radical production by 
DOX (Olson and Mushlin, 1990; Zucchi and Danesi, 2003). 
11 
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1.3.1.2 Cardiac Damage by Free Radicals 
It has been suggested that free radical damage induced by DOX correlates more 
closely to its cardiotoxic effects than its anti-tumour effects (Hortobagyi, 1997). Keizer et 
al. (1990) reported that lipid peroxidation has been observed in the heart tissue of mice 
for both acute and chronic models of DOX-induced cardiotoxicity, but not in the tumor 
cells and liver tissues of the same mice. This can be explained by the relative lack of 
antioxidant mechanisms, including reduced glutathione (GSH), superoxide dismutase or 
catalase, in the heart when compared to other organs such as liver and kidney (Dorr, 1996; 
Sarvazyan, 1996; Hortobagyi, 1997; DeAtley et al” 1999). 
\ 
The lipid bilayer cell membrane is believed to be the first target of free radicals 
generated by DOX (Xu et al, 2001). Lipid peroxidation may lead to various damages, 
such as losing polyunsaturated fatty acids (Bruch and Thayer, 1983), generating the 
cross-linking of lipid-lipid and lipid-protein moieties (Bruch and Thayer, 1983), and 
increasing the molar ratio of cholesterol to phospholipid (Garcia et al., 1997)，in the 
structure of cell membrane (Xu et aL, 2001). Lipid hydroperoxides, formed from a chain 
reaction of hydrogen peroxides, increase cell membrane permeability and form cytotoxic 
aldehydes such as malondialdehyde, 2-alkenals and 4-hydroxyalkenals. Theses aldehydes 
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can affect membrane proteins and thereby inactivating receptors and membrane-bound 
enzymes (Straghan et al., 1996; Horenstein et al., 2000). The beta-adrenergic receptor is 
one of the membrane proteins involving in the signaling system and vital in heart 
function. DOX impairs its function as it changes the physical properties of the cell 
membrane (Fujita et al, 1991; Xu et al., 2001). 
Free radicals also cause mitochondrial dysfunction, resulting in increase of 
mitochondrial membrane permeability and the release of superoxide anion ( ( V ) 
(DeAtley et al, 1999). Previous study showed that in the presence of DOX and NADH, 
Oz " were formed in the mitochondrial fraction of rat hearts (Doroshow, 1983; Olson and 
Mushlin, 1990). Moreover, free radicals also impair the function of SR in the 
sequestration of Ca^ "^ . Experiment on rat cardiac SR showed that pre-incubation with 
DOX (40 i^ lM) and NADH/NADPH dehydrogenases for 30 minutes inhibited calcium 
sequestration by 70 %. Incubation with catalase and free radical scavengers, 
N-acetylcysteine (NAC) and glutathione, attenuated the inhibition of calcium 
sequestration (Harris and Doroshow, 1985). Therefore, impairments of cardiac 
contractility (decreased Ca^ "^  supply) and relaxation (increased 
level of Ca2+ at cardiac 
tissues) are resulted from the free radicals induced cardiac dysfunction (Olson and 
Mushlin, 1990). 
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1.3.2 Induction of Apoptosis 
Apoptosis has recently been shown to be involved in DOX-induced carditoxicity 
(Kang et al., 2000). This is further supported by different in vitro and in vivo models of 
DOX-induced cardiac toxicity, as demonstrated by the occurrence of various apoptotic 
features, including mitochondrial dysfunction, DNA fragmentation and caspase activation 
(Kerr et al., 1972; Thompson, 1995; Vaux and Strasser, 1996; Kim et al., 2000; Youn et 
al., 2005). 
1.3.2.1 Characteristics and Pathway of Apoptosis 
Apoptosis, also known as programmed cell death, is an active and highly regulated 
mechanism, which is of vital importance to life, including the embryonic development, 
maintenance of homeostasis and pathogensis of various diseases (Haunstetter and Izumo, 
1998; Gill et al., 2002). Cells undergoing apoptosis are different from that of necrosis in 
both morphological and biochemical aspects. The morphological features of apoptosis are 
cell shrinkage, chromatin condensation, DNA fragmentation, membrane blebbing and 
formation of apoptotic bodies (Wyllie, 1980; Enari et al, 1998; Haunstetter and Izumo, 
1998; Saraste and Pulkki, 2000). DNA fragmentation is the biochemical hallmark of 
14 
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apoptosis. The activation of endogenous endonucleases leads to the cleavage of 
intemucleosomal DNA segments (Faded and Orrenius, 2005). Other characteristic 
features of apoptosis can be observed in cells undergoing apoptosis, including the 
extemalization of phosphatidylserine on the outer plasma membrane and activation of 
caspases (Bishopric et al., 001; Gill et aL, 2002; Kang and Izumo, 2003). 
Apoptosis can be initiated by two distinct pathways: the death receptor (extrinsic) 
pathway and the mitochondrial (intrinsic) pathway (Figure 1.3). The extrinsic pathway is 
initiated by a ligand, such as Fas ligand (FasL) or tumour necrosis factor a (TNF-a), 
binding to a membrane-bound death receptor, such as Fas or TNF-a receptor. The 
intrinsic pathway is mediated by the mitochondrial cytochonrome c release in response to 
extrinsic stimuli, such as oxidative stress. Both the extrinsic and intrinsic pathways lead 
to the activation of a common downstream pathway, which further execute apoptosis in 
terms of the morphological and biochemical changes of the cells (Reed and Patemostro, 
1999; Haunstetter and Izumo, 2000; Bishopric et al., 2001; Kang and Izumo, 2003). 
1.3.2.2 Mitochondria and Apoptosis 
Mitochondria play a crucial role in inducing apoptosis. Apoptosis can be initiated by 
15 
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mitochondria through two pathways. One is involved the release of cytochrome c to the 
cytocol, which forms an activation complex with pro-caspase-9 and apoptotic-protein 
activating factor (Apaf-1). In the presence of sufficient ATP, caspase-9 is then activated 
and active ‘apoptosome，is formed. Apoptosome activates caspase-3, which is the central 
caspase responsible for the execution of apoptosis. Active caspase-3, acting as a terminal 
effector of apoptosis, cleaves different substrate proteins and also further deliver the 
apoptotic signal by activating other pro-caspases (Cook et ai, 1999; Susin et al” 1999; 
Haunstetter and Izumo, 2000; Bishopric et al” 2001). The second pathway is initiated by 
the opening of mitochondrial permeability transition pore (MPTP). This MPTP opening 
subsequently leads to the loss of mitochondrial membrane potential, release of apoptosis 
_ inducing factor (AIF) and induction of apoptotic alternations in the nucleus and the cell 
membrane (Valen, 2003). The mechanism of MPTP opening is thought to be associated 
with and regulated by the Bcl-2 family proteins. 
The Bcl-2 family proteins consist of pro-apoptotic proteins, like Bax and Bid that 
facilitating MPTP by inducing release of cytochrome c, and anti-apoptotic proteins, like 
Bcl-2 and Bcl-xL that inhibit apoptosis by blocking of cytochrome c release (Oltvai et ai, 
1993; Childs et al., 2002). Homodimers of Bax (Bax/Bax) can form large pores in the 
outer mitochondrial membrane and promote the release of cytochrome c, thereby 
16 
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inducing apoptosis. The formation of heterodimers of Bcl-2/Bax can inhibit apoptosis by 
prohibiting the formation of pore in the outer membrane (Childs et al, 2002; Gill et al, 
2002; van, V et al； 2005). 
1.3.2.3 Caspases and Apoptosis 
Caspases are a group of proteases, present as inactive pro-caspases in the cell. 
Caspases are activated during apoptosis by proteolytic cleavage of their pro-caspase. 
They are classified as initiator caspases, such as caspase-8 and -9 and effector caspases, 
such as caspase-3, -6 and -7 (Ly et al., 2003). Caspase activation can be characterized in 
two pathways, the extrinsic pathway and the intrinsic pathway. In the extrinsic pathway, 
一 
death receptors activate caspase-8 and/or -10，subsequently activating executioner 
caspases such as caspase-3. In the intrinsic pathway, cytochrome c released from 
mitochondria activates caspase-9, which further activates the downstream effector 
caspase-3 (Hengartner, 2000; Moretti et al” 2002). The activation of caspase-3 causes the 
cleavage of various cellular components, leading to the morphological alterations of 
apoptosis including condensation of chromatin, fragmentation of DNA and destruction of 
cytoskeleton (Laugwitz et al., 2001). Previous study reported that the contractile 
performance of ventricular myocytes is directly affected by the activation of caspase-3 
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(Narula et al., 1996; Kalyanaraman et al., 2002). � 
1.3.2.4 Apoptosis and DOX-induced Cardiotoxicity 
Emerging studies indicate the role of apoptosis in DOX-induced cardiotoxicity. 
Cardiomyocyte apoptosis is thought to lead to the development of heart failure (Delpy et 
al., 1999; Axola et al., 2000). DOX has been shown to cause apoptosis in the rat heart and 
in a rat ventricular cell line (Uendo et al., 2006). In addition, treatment with DOX 
induced apoptosis in endothelial and cardiac cells, as demonstrated by the characteristics 
of caspase activation and intemucleosomal DNA degradation (Kotamraju et al., 2000). In 
an acute in vivo model, apoptosis was demonstrated and mediated by the mitochondrial 
dependent pathway, as indicated by the release of cytochrome c into cytosol of 
DOX-treated rats (Childs et al., 2002). Apoptosis has also been shown in DOX-treated 
H9C2 cells and it is thought to be associated with the induction of Bax and activation of 
caspase-3 (Unverferth et al.，1983; Arola et al., 2000). Features of apoptosis, including 
the contraction and ring formation of the nuclei, have been observed in patient heart 
sample within 24 hours following DOX administration (von et al., 1999; Kotamraju et al., 
2000; Li and Singal, 2000; Kluza et al” 2004). Various reports suggested that 
DOX-induced apoptosis is mediated by the formation of ROS (Kumar et al., 2001; Liu et 
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al., 2002). Pretreatment with antioxidants such as probucol and melatonin 
(Dragojevic-Simic et al” 2004), free radical scavengers such as amifostine (Delia et al., 
1999) or iron chelator such as dexrazoxane (Servant et al., 2004) have been reported to 
decrease DOX-induced cardiotoxicty. However, increasing evidences elucidated the fact 
that cardiac injury caused by DOX could not be completely prevented by a general 
decrease in oxidative stress, suggesting other mechanisms of DOX-induced cardiotoxicity 
are involved (Speyer and Wasserheit, 1998). 
SECTION 1.4 Strategies to Reduce DOX-induced Cardiotoxicity 
‘ Remarkable efforts have been made in preventing or minimizing the cardiotoxicity 
induced by DOX without attenuating its anti-tumour effects. Strategies on three main 
areas have been concentrated to prevent the cardiac toxicity induced by DOX, including 
the dosage optimization and schedule modification, synthesis of anthracycline analogues 
and the development of cardioprotective agents (Singal et aL, 2000). 
1.4.1 Dosage Optimization and Schedule Modification 
Among different preventive measures, limiting the cumulative dose of DOX is the 
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most accepted methods (Von Hoff et al” 1979; Krischer et al” 1997). It has been 
suggested to restrict the maximum cumulative dose to 450-550 mg/m to reduce the 
cardiac toxic effects of DOX (Lipshultz et al., 2005; Wouters et al., 2005). However, no 
lifetime safe dose can be found to absolutely prevent the occurrence of cardiotoxcity (Von 
Hoff et al., 1979; Speyer and Wasserheit, 1998). Besides, patients with increased cardiac 
risk factors, including age > 70，previous DOX, previous cardiac diseases, high blood 
pressure or diabetes, and previous irradiation of chest wall, have also been suggested to 
limit or withhold DOX treatment (Wouters et al, 2005). 
The introduction of schedule modification is due to the hypothesis that different 
mechanisms are associated with the anti-tumour effects and cardiac toxic effects of DOX. 
一 -
Speyer and Wasserheit (1998) suggested that the anti-tumour effects and the chronic 
cardiotoxicity of DOX are related to total DOX exposure and peak DOX concentration 
respectively. However, utilizing slow infusion instead of bolus administration is still 
under discussion. Although continuous infusion decrease peak DOX concentration, it 
would extent the exposure time of cardiomyocytes to DOX, which may prevent the 
recovery of cardiomyocytes (Shapira et al., 1990). Different findings have been reported 
from studies of continuous infusion. Previous report demonstrated that patients receiving 
DOX by 6 hours infusion showed significant reduction in carditoxicity (Lipshultz et al., 
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2002), whereas another study on children with acute lymphoblastic leukemia showed no 
significant difference in cardiotoxicity developed between groups treated with continuous 
48 hours infusion or bolus infusion (Weiss, 1992; Singal et al., 2000). 
1.4.2 Anthracycline Analogues 
Over 2000 anthracycline analogues have been developed today in order to increase 
the anti-tumour efficacy and to reduce cardiac toxicity, such as idarubicin, epirubicin, 
pirarubicin, aclarubicin and zorubicin (Ganzina, 1983; Lahtinen et aL, 1991; Cottin et al, 
1998). Epirubicin, one of the most extensively studied, shows promising effects in 
preclinical and clinical trials (larussi et al.，2001). Epirubicin is less cardiac toxic than 
DOX and its cardiotoxicity increase at cumulative dose of 900-1000 mg/m^ (Schimmel et 
al., 2004; Wouters et al., 2005). 
1.4.3 Cardioprotective Agents 
There are numerous potential cardioprotective agents that have been tested or under 
investigations, including monohydroxyethylrutoside (monoHER), N-acetylcysteine 
(NAC), carvedilol, probucol, amifostine, etc (Hasinoff, 1989; Sobol et al, 1992; Yeung et 
21 
Ch 1 General Introduction 
al., 1992; Chakrabarti et al., 2001). 
The clinically approved cardioprotective agent dexrazoxane (ICRF-187， 
[(+)-1,2-bis(dioxopiperazinyl-1 -yl) propane]) is a cyclic analogue of 
ethylenediaminetetraacetic acid (EDTA). It is able to undergo rapid hydrolysis in the 
heart to a strong chelating agent that removes Fe^ "^  and Fe^ "^  from DOX-iron complexes 
(Myers et al” 1982; Eliot et al., 1984; Yeung et al., 1992), which is believed to be one of 
the important mechanisms of DOX-induced cardiotoxicity. DOX-iron complex has been 
demonstrated to cause local oxidation destruction through a free-radical mechanism by 
binding on the important cellular structures like DNA and cell membranes (Yeung et al., 
1992). Dexrazoxane has been proven to protect against the cardiotoxicity induced by 
DOX in different animal models, including the mouse, rat, rabbit, dog and miniature pig 
(Jaenke, 1976; Herman and Ferrans 1983a; Herman and Ferrans, 1983b; Herman et al., 
1985; Jensen, 1986; Villani et al., 1990). However, dexrazoxane could not provide 
complete cardiac protection, as indicated by the patients treated with higher dose of 
dexrazoxane experienced cardiac complications (Parsa et al., 2003; Li et al,, 2006). 
Erythropoietin (EPO) is an endogenous cytokine produced by the adult kidney that 
is responsible for the proliferation, survival and differentiation of erythroid progenitor 
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cells. The receptor of EPO has also been found in nonhaematopoietic tissues, including 
the heart, indicating that EPO signaling may play potential roles in these tissues (Brines 
et al., 2000; Siren et al., 2001). Previous studies have elucidated the protective role of 
EPO in the brain (Celik et al., 2002; Gorio et aL, 2002), spinal cord (Grimm et al” 2002), 
retina (Ogilvie et al” 2000), skeletal muscles (Parsa et al., 2003; Parsa et al., 2004). EPO 
has also been demonstrated to exert protective effects in ischemic and infarcted hearts by 
inhibition of apoptosis (Parsa et aL, 2004; Li et al., 2006). Until recently, EPO was 
reported to protect against cardiac dysfunction in rats and mice treated with DOX 
(Hamed et aL, 2006; Li et al, 2006). 
, SECTION 1.5 Thrombopoietin 
Experiment on plasma transfusion in the late 1950s revealed that plasma from 
bleeding or thrombocytopenic rats induced thrombocytosis in the receiving animals, 
indicating the presence of a humoral regulator of thrombopoiesis (Kelemen et al” 1958). 
In 1958, thrombopoietin (TPO) was first introduced to represent a humoral substance 
capable of increasing platelet production (Kaushansky, 1995; Kaushansky, 2005). The 
receptor c-mpl was identified in 1992，leading to the cloning of its ligand, and TPO was 
yield two years later (Lok et aL, 1994; Geddis et aL, 2002; Fishley and Alexander, 2004). 
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TPO is a polypeptide with two recognizable domains. The amino-terminal domain 
exerts the biological activity of TPO and has 20 % identity and 25 % sequence similarity 
with human EPO in their receptor-binding regions (Figure 1.4) (Kaushansky, 1998; 
Basser and Begley，2001). The carboxyl-terminal domain does not share homology to any 
known proteins but it is vital for maintaining protein stability (Kaushansky, 1998; Basser 
and Begley, 2001). There are two forms of TPO under investigation in the clinical trials, 
and they are the recombinant human thrombopoietin (rhTPO) and PEG-conjugated 
recombinant human megakaryocyte growth and development factor (PEG-rhMGDF). 
They have the same receptor-binding regions but with different structures in 
carboxyl-terminal domains. rhTPO is the complete polypeptide of the human TPO, while 
___ PEG-rhMGDF is a truncated protein consisting of the receptor-binding region only. 
PEG-rhMGDF is chemically modified and conjugated to the polyethylene glycol (PEG) 
(Choi et al., 1995; Debili et al, 1995; Kaushansky et al., 1995; Ku et al” 1996; Sitnicka 
et al., 1996; Miyakawa et al., 2001). 
TPO regulates all aspects of megakaryocyte development. It promotes the survival, 
proliferation, differentiation of haematopoietic stem cells to mature megakaryocyte 
(Kaushansky et al., 1994; Kuter et al” 1994; Broudy et al., 1995; Kuter and Begley, 
2002). Besides increasing the size and number of megakarocytes, TPO is responsible for 
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Stimulating platelet-specific marker expression and endomitosis in megakaryocytes, and 
acting as a potent megakaryocyte colony-stimulating factor (Ku et ai, 1996; Sitnicka et 
al, 1996; Rasko et al., 1997; Kuter and Begley, 2002). In the presence of other 
haematopoietic growth factors such as EPO and stem cell factor, TPO functions 
synergistically with them on the growth of myeloid and erythroid precursors (Majka et al,’ 
2002; Siguijonsson et al., 2004). 
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Figure 1.1 Chemical structures of Daunorubicin (A) and Doxorubicin (B). 
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mitochondrial (intrinsic) pathway (modified from Kang and 
Izumo, 2003). 
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Figure 1.4 The structures of thrombopoietin (TPO) and erythropoietin (EPO) 
and their structural similarity are shown in the receptor-binding 
region (adapted from Geddis et al., 2002). 
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C H A P T E R 2 
Hypotheses and Objectives 
Various clinical measures have been taken to minimize DOX-induced 
cardiotoxicity, including dosage optimization and schedule modification, synthesis of 
anthracycline analogues and development of new cardioprotective agents. The 
invention of new cardioprotective agents is ongoing to develop one with less side 
effects and without interfering the anti-tumour effects of DOX. We hypothesized TPO 
一 as the new cardioprotective agent and our rationales were that: 
1. TPO has anti-apoptotic effects on haematopoietic stem cells and megakaryocytes 
mediated by the Akt pro-survival pathway (Latronico et al.’ 2004). The Akt 
pathway has been known to exert protective effect on cardiomyocyte survival 
(Lok et al； 1994; Wada et aL, 1995; Rouleau et al., 2004). 
2. TPO has strong sequence homology with erythropoietin (EPO) with 20 % identity 
and 25 % sequence similarity in their receptor-binding region. It was reported that 
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the mitogenic effects of TPO may exert on cells by binding to EPO receptor 
(Rouleau et al, 2004; Li et al” 2006). EPO has recently been shown to protect 
DOX-treated rats and mice from cardiac dysfunction (Georgakopoulos and Kass, 
2001). 
In the present study, the three main objectives were as follows: 
1. To examine the effects of TPO on DOX-induced cardiotoxicity in the in vitro 
models of cardiomyocytes, rat H9C2 cell line and primary, neonatal rat 
ventricular beating myocytes. 
The effect of TPO on DOX-induced injury in H9C2 cells was measured by 
the cell viability MTT assay. The effect of TPO on the beating function of 
primary ventricular myocytes was studied. 
2. To establish an in vivo mouse model of DOX-induced cardiotoxcitiy and to 
study the effects of TPO on the in vivo model. 
The effects of TPO on the protection against DOX-induced cardiotoxicity 
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were assessed by the mortality rate，body weight, heart weight, blood cell counts, 
cardiac hi stop atho logy and cardiac functional parameters (heart rate, fractional 
shortening, cardiac output, left ventricular end-diastolic dimension and left 
ventricular end-systolic dimensions). 
3. To investigate the mechanism of TPO on myocardial protection in the in vitro 
model of rat H9C2 cell line and in vivo model. 
The protective effect of TPO against DOX-induced cardiac damage in H9C2 
cells was performed by assays of annexin V，active caspase-3 and mitochondrial 
membrane potential (A平m). In the in vivo model, effect of TPO was analyzed by 
一 -
the TUNEL assay. 
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C H A P T E R 3 
Methodology 
SECTION 3.1 Methods 
3.1.1 Culture of Rat H9C2 Myoblast Cell Line and Primary Neonatal Rat 
Cardiomyocytes 
3.1.1.1 Maintenance of Cell Line 
H9C2 cells (American Type Tissue Collection, Manassas, VA, USA, Cat no. 
CRL-14446) was maintained in Iscove's modified Dulbecco's medium (IMDM) 
supplemented with 10 % fetal bovine serum (FBS), 100 U/mL penicillin, 100 |Lig/mL 
streptomycin, and at 37 °C in a 5 % CO2 humidified atmosphere. All media and 
culture reagents were purchased from Gibco (Grand Island, NY, USA) unless 
otherwise specified. Cells were cultured in 25 cm flasks and were subcultured when 
they reached about 70 % confluence. H9C2 cells were detached by using 0.25% 
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(w/v) Trypsin-0.53 mM EDTA solution and the cell suspension was centrifuged at 
400 X g for 5 minutes. Cell pellet was resuspended in fresh IMDM and cells were 
subcultured at a ratio of 1:4. 
3.1.1.2 Culture of Primary Neonatal Rat Cardiomyocytes 
Heart ventricles were dissected from 1-day-old neonatal Sprague-Dawley rats. 
The ventricles were washed with phosphate-buffered saline (PBS) and digested with 
2 mL collagenase (200 U/mL) and Dulbecco's modified Eagles's medium (DMEM) 
at 37 °C in two 1-hour-digestion steps. The pooled cell suspensions were spun down 
_ by centrifugation at 400 x g for 7 minutes. The cell pellet was resuspened in DMEM 
containing 10 % FBS. Fibroblasts were removed by adhesion for 1 hour in a 75 cm^ 
flask at 37 °C. Non-adhered cells were allowed to attach for another 1 hour. 
Enriched myocytes were seeded in 24-well plates at a density of 2 x 10^ cells/well in 
DMEM and Medium 199 in a ratio of 4:1，with 5 % FBS and 10 % horse serum. 
Myocytes were cultured with daily medium change. After 5-6 days, treatment 
studies were performed when the myocytes beat at relatively steady rates. 
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3.1.2 Effects of Thrombopoietin on Cell Viability of Rat H9C2 Myoblast 
Cell Line and Beating Rates of Primary Rat Cardiomyocytes 
3.1.2.1 Cell Viability assay 
H9C2 cells were plated at 2 x lO^ cells/well in 24-well plates for 24 hours 
before experiment. Cells were pre-treated with or without TPO at concentrations of 
5, 10，50 or 100 ng/mL for overnight (Peprotech, Rocky Hill, NJ, USA) or 
dexrazoxane at 50 ^g/mL for 30 minutes (Chiron, Amsterdam, The Netherlands). 
Cells were then exposed to 5 iig/mL of DOX (Ebewe Pharma Ges, Austria) for 
another 24 hours. Cell viability was determined by the MTT assay. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 250 jig/mL; 
Sigma, St Louis, MO, USA) was added and incubated for 4 hours at 37 ®C in 5 % 
CO2 incubator. The culture medium was removed, dimethyl sulfoxide (DMSO, 200 
I^L; Sigma) was then added to dissolve the dark blue formazan crystals. The optical 
density was measured by using a microplate reader (Dynatech MR5000, Chantilly, 
VA, USA) at 570 nm. Results are expressed as percentage viability of control cells. 
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3.1.2.2 Beating Rate of Primary Beating Cardiomyocytes 
The beating cells were pre-treated with TPO (50 or 100 ng/mL) or dexrazoxane 
(5.8 |ig/mL) for 1 hour, followed by treatment of a single dose of DOX (1 jiM or 
0.58 |j.g/mL). The culture medium was changed with fresh TPO or dexrazoxane 
daily. The beating rates and morphology of each colony of cardiomyocytes were 
recorded on CompactFlash 256MB memory cards in a digital camera connecting to 
a phase contrast inverted microscope. The beating rates of each group of cells were 
recorded for 40 seconds, and measured at 0 hour (pre-DOX treatment), 24 hours and 
48 hours (post-DOX treatment). Results are expressed as the beating rate in 
percentage relative to that of the same colony at 0 hour. 
3.1.3 Effects of Thrombopoietin on the Protection Against DOX-induced 
Heart Injury In Vivo 
3.1.3.1 Animals 
Male Balb/c mice (9-10 weeks of age) were obtained from the Laboratory 
Animal Services Centre of The Chinese University of Hong Kong. They were 
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housed in an animal house maintained at a constant temperature of 23 士 2 °C and a 
regular 12-hour-light-dark cycle. They were allowed to freely access food and water 
ad libitum. Experiments were approved by the Animal Research Ethics Committee, 
The Chinese University of Hong Kong. 
3.1.3.2 Experimental Protocol 
The mice were randomly divided into 4 treatment groups: Control, DOX, 
DOX+TPO and TPO. The DOX group were administrated with a single 
intraperitoneal (i.p.) dose of 20 mg/Kg of DOX on Day 0. The DOX+TPO group 
z received a single dose of DOX (20 mg/Kg, i.p.), and 3 doses ofTPO (12.5 ^g/Kg, 
i.p., dissolved in normal saline), on 1 day before (Day-1), Day 1 and Day 3 after 
DOX treatment. The Control group was injected with the same volume of normal 
saline instead of DOX. The TPO group was given 3 doses ofTPO (12.5 |ig/Kg, i.p.) 
but not subjected to DOX treatment. Animal mortality was monitored daily for 5 
days during the experiment. The body weight of mice at Day - 1 and Day 5 was 
recorded. For the survival rate, an independent experiment was performed for 8 days. 
Mice of the 4 treatment groups were monitored without any sample collection or 
daily manipulation. 
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3.1.3.3 Echocardiography 
Transthoracic echocardiography was performed on 4 groups of mice at baseline 
(Day -1 ) and Day 5 by using an ultrasound system (Sonos 7500, Philips Ultrasound, 
Bothell, WA) equipped with a linear array 6-15 MHz transducer. The mice were 
maintained at a conscious state during the experiment. They were trained several 
times a day from 3 days before baseline echocardiography. The chests of mice were 
shaved and mice were blind-folded during training. They were gently held in the 
supine position with a steady heart rate (HR, ranged from 550 to 650 beats/min) 
(Herman et al., 1994). Pre-warmed ultrasound-coupling gel (34 Bucher Medical 
Mbnet, Switzerland) was applied and the transducer was put on the precordium. The 
interrogation depth was set at 3 cm. By adjusting time gain compensation, 
two-dimension parasternal long axis view was visualized. Two-dimension targeted 
M-mode echocardiographic images were recorded at the level of papillary muscles 
and at a sweep speed of 100 mm/s. Pulsed wave Doppler tracing on aortic flow were 
then recorded at aortic root. All images were acquired and transferred to Xcelera 
image management workstation (Philips medical Systems, Nederland B.V., The 
Netherlands) for off-line analysis. All measurements were done according to the 
American Society of Echocardiography leading edge method. Left ventricular 
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end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), 
and left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic 
volume (LVESV) were measured. HR was measured by counting aortic flow for 
consecutive 2 seconds in pulsed wave Doppler tracing. The fractional shortening (FS) 
and cardiac output (CO) were calculated by using the followings formula: FS = 
[(LVEDD - LVESD) / LVEDD] x 100 % and CO = HR x (LVEDV - LVESV) 
respectively. 
3.1.3.4 Blood Cell Counts 
一一 Peripheral blood was collected at baseline and Day 5 from the tail veins of 
animals. Red blood cells (RBC), white blood cells (WBC) and platelets were counted 
by light microscope. 
3.1.3.5 Histopathology 
Five days after DOX treatment, all mice were sacrificed under general 
anesthesia using ketamine and xylazine. The heart was dissected, all main vessels 
were removed, and the heart weight was measured. The heart was flushed with PBS, 
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fixed in 4 % formaldehyde and embedded in paraffin. Cross sections (5 pim) of were 
cut and subjected to dewax and rehydrating processes using xylene, a graded series 
of ethanol and double distilled water. Sections were stained with hematoxylin/eosin, 
then mounted and examined using a light microscope. The frequency and severity of 
DOX-induced myocardial injury were investigated by a blinded investigator. The 
severity of cardiac damage was graded with a scoring system (Chan et al” 1996) 
according to the percentage of myocyte vacuolization and myofibillar loss as 
follows: 0 : no abnormality; 1 : < 5 %; 1.5 : 5-15 %; 2 : 16-25 %; 2.5 : 26-35 %; 3 : 
> 55 % of the myocytes showing damage. Eight randomly assigned areas of each 
section and 2 sections per heart were analyzed. 
3.1.4 Effects of Thrombopoietin on Apoptosis and Mitochondrial Integrity 
of Rat H9C2 Myoblast Cell Line and Apoptosis In Vivo 
3.1.4.1 Determination of Externalized Phosphatidylserine 
Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, 
USA) was employed to quantify externalized phosphatidylserine according to the 
manufacturer's instruction. H9C2 cells were seeded at 1 x 10^  cells/mL in EMDM 
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supplemented with 5 % FBS. Cells were pre-incubated with or without TPO (100 
ng/mL) for 2 hours, and then treated with DOX (0.58 i^g/mL) for another 24 hours. 
Cells were harvested and resuspended in 100 ^L of Ix Annexin V Binding Buffer at 
a density of 1 x 10^ cells/mL. Five |LIL of Annexin V-FITC and 5 }IL of propidium 
iodide (PI) were added to cells and incubated for 15 minutes at room temperature in 
the dark. Following incubation, 400 i^L of Ix Annexin V Binding Buffer were added 
to the stained cells. Cells were then subjected to FACScan flow cytometer using 
LYSIS II software (BD Immunocytometry Systems; BDIS, San Jose, CA, USA), 
with green fluorescence of FITC being measured at 530 nm (FLl) and red 
fluorescence of PI being measured at 585 nm (FL2). Ten thousand events were 
acquired for each sample, while CellQuest software was used for analyzing the 
results (BDIS). 
3.1.4.2 Determination of Active Caspase-3 Expression 
H9C2 cells were seeded at 1 x 10^ cells/mL in IMDM supplemented with 5 % 
FBS. Cells were pre-treated with or without TPO (100 ng/mL) for 2 hours, and then 
treated with DOX (0.58 |ig/mL) for another 24 hours. Five hundred |iL of Ix FACS 
Permablizing Solution (BD Pharmingen) were added to one million cells for 10 
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minutes at room temperature in the dark. They were washed with PBS and incubated 
with 10 |iL of PE-conjugated polyclonal antibody against active Caspase-3 (BD 
Pharmingen) for 30 minutes at room temperature in the dark. Cells were then 
washed with PBS, and fixed in 400 |iL of 1 % paraformaldehyde in PBS before flow 
cytometry analysis. Ten thousand events were acquired. 
3.1.4.3 Assessment of Mitochondrial Integrity 
Mitochondrial integrity was monitored by ApoAlert™ Mitochondrial 
Membrane Sensor Kit (BD Clontech, Mountain View, CA, USA) according to the 
manufacturer's instructions. After pre-incubation with or without TPO (100 ng/mL) 
for 2 hours, DOX (0.58 |ig/mL) was added to H9C2 cells for another 2 hours. 
Culture medium was then discarded and cells were washed to remove DOX. Fresh 
medium containing TPO was added to cells for another 22 hours. H9C2 cells were 
harvested, washed with PBS, and incubated in 1 mL of diluted JC-1 at a density of 
1x10^ cells/mL. They were incubated for 15 minutes at 37 in a 5 % CO2 incubator. 
Cells were washed with Incubation Buffer, resuspended in 1 mL of Incubation 
Buffer and analyzed by flow cytometry. The monomers and aggregates of JC-1 were 
detected at green fluorescence in FLl and red/orange fluorescence in FL2 
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respectively. Ten thousand events were acquired. 
3.1.4.4 TUNEL assay 
The terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) 
assay was performed to detect apoptotic cell death with the In Situ Cell Death 
Detection Kit, Fluorescein (Roche Diagnostics GmbH, Penzberg, Germany) according 
to the manufacturer's instructions. An independent experiment was performed on 4 
groups of animal (n = 5) receiving the same treatment with slight modification. Mice 
only received 2 doses of TPO (Day - 1 and Day 1) and sacrificed at Day 3 after 
DOX-treatment. A pilot study showed that DOX-induced apoptotic cell death at this 
time point was most prominent by the detection of the TUNEL assay. Hearts were 
dissected, flushed with PBS and fixed in 4% formaldehyde. Paraffin-embeded heart 
sections (4 p.m) were subjected to the TUNEL assay. The sections were undergo 
dewax and rehydrating process by the use of xylene, a graded series of ethanol and 
double distilled water. Sections were permeabilized in a freshly-prepared solution 
containing 0.1% Triton X-100 and 0.1% sodium citrate for 8 minutes, followed by the 
incubation with freshly-prepared TUNEL reaction mixture for 1 hour at 37 ®C in a 
humidified chamber in the dark. Sections were then mounted, and investigated under 
43 
Ch 3 Methodology 
a Zeiss Axioplan 2 microscope linked to a SPOT-Cooled Colour Digital Camera 
(Diagnostic Instruments, Sterling Heights, MI, USA). Six sections from each heart 
were examined, all TUNEL positive cells were counted for the whole section and the 
section area was computed by SPOT Advance Software (Version 4.1.3，Diagnostic 
Instruments Inc.). Results are expressed as the number of apoptotic cells per unit area 
(mm^). 
3.1.5 Statistical Analysis 
Statistical analyses were performed using the SPSS software package (SPSS 
一 Inc，Chicago, IL，USA) or SigmaPlot software package (SPSS Inc). The effects of 
TPO on in vitro models of cardiomyocytes were analyzed by the Kruskal-Wallis 
Ranking test or Friedman test, with post hoc comparisons by Mann-Whitney test or 
Wilcoxon Signed Ranks test, respectively to evaluate significant comparisons. 
Bonferroni correction was applied to adjust for multiple comparisons (Figures 4.1， 
4.2, 6.1, 6.2 and 6.3，e.g. p = 0.017 for 3 comparisons on DOX vs. Control, 
DOX+TPO vs. DOX, and TPO vs. Control). For in vivo model, Wilcoxon Signed 
Ranks test was applied to determine the significance of differences obtained at 
Day - 1 and Day 5 of the same animal in heart function parameters and blood cell 
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counts, and differences between groups at Day 5 were analyzed by Mann-Whitney 
test (Table 5.1 and 5.2). Comparison between survival rates of mice was performed 
using the Log Rank test. Multiple modeling was used for examining effects of TPO 
on trends of daily heart rate，and the Likelihood Ratio test was used to assess the 
significance of estimates at the 5 % level. The Mann-Whitney test was used for 
comparison between groups of number of positive apoptotic nuclei stained. 
Difference in cardiomyopathy scores were analyzed by Kruskal- Wallis Ranking test 
and Mann-Whitney test (Table 5.3). 
.一 -
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C H A P O T E R 4 
E f f e c t s of T h r o m b o p o i e t i n on C e l l 
Viability of Rat H9C2 Myoblast Cell Line 
and Beating Rates of Primary Neonatal 
Cardiomyocytes 
SECTION 4.1 Results 
4.1.1 Effects of TPO on DOX-induced Cell Death 
Cell survival after DOX treatment was determined by MTT assay. 
Administration of DOX (5 |ig/mL) for 24 hours decreased H9C2 cell viability to 26.2 
土 1.1 o/o from control (Figure 4.1，n = 4，p < 0.001). The cell viability was recovered 
by pre-treatment of TPO in a dose-dependent manner, and at 100 ng/mL of TPO, cell 
viability was increased to 85.6 士 4.4 % (* p = 0.016). Dexrazoxane (50 |Lig/mL) 
increased H9C2 cell viability to 82.8 士 2.0 %. 
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4.1.2 Effects of TPO on the Beating Rates of Primary Cardiomyocytes 
The addition of DOX significantly reduced the beating rates of primary 
cardiomyocytes at 24 hours (Figure 4.2). After the change of fresh culture medium 
without DOX at 24 hours, the beating rates of cardiomyocytes decreased further to 
15.2 土 16.9 % (n = 10，# p < 0.001 for both time points when compared to the 
Control cultures). Pre-treatment with 5.8 |ig/mL of dexrazoxane, or 50 ng/mL or 100 
ng/mL of TPO did not protect against the DOX-induced reduction of beating rate at 
24 hours. However, they significantly increased the beating rates of DOX-treated 
cardiomyocytes to 69.2 土 30.4 %, 43.2 士 16.8 % and 47.8 土 22.9 % respectively at 
48 hours (* p = 0.001，* p = 0.002 and * p = 0.002 respectively when compared with 
those treated with DOX). Dexrazoxane or TPO alone did not influence the beating 
rates of the cardiomyocytes. 
SECTION 4.2 Discussion 
DOX-induced cardiotoxicity has been demonstrated in different models of 
cultured cells (Repine, 1991), isolated heart preparations (Singal et al., 1987; Pouna et 
al., 1996)，and animal models (Jeremias et aL, 2005; Planavila et al., 2005). H9C2 
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embryonic cell line have been used as an in vitro model for studying cardiac 
hypertrophy, gene expression and apoptosis (Hescheler et al., 1991; Sipido and 
Marban, 1991; Wang et al., 1999a), as they possess electrophysiological and 
biochemical properties of cardiac muscle (Wang et aL, 1999b). Neonatal rat 
cardiomyocytes have been studied on the cellular and molecular mechanisms of 
cardiac alternations induced by oxidative stress or drug-induced carditoxicity 
(Yamana et al., 1985). They provide the advantages of comparatively easier culture 
than adult cardiomyocytes (Yamashita et al, 1994) and highly stable phenotype of 
neonatal cardiomyocytes (Parsa et al., 2003; Tramontane) et aL, 2003). In this study, 
we employed H9C2 cell line and primary neonatal rat cardiomyocytes as the in vitro 
^ models to study the efficacy of TPO, a haematopoietic/megakaryocytopoietic growth 
factor, against DOX-induced cardiotoxicity. 
Recent studies on several growth factors, such as insulin-like growth factor I， 
,hepatocyte growth factor and erythropoietin, shows cardioprotection from apoptosis 
in the failing myocardium. Erythropoietin (EPO) have also been shown to protect and 
promote cardiomyocytes (Lok et al, 1994; Wada et al., 1995; Rouleau et al., 2004). 
Of relevance, the strong sequence homology between EPO and TPO may allow TPO 
to exert its mitogenic effects by binding to EPO receptor (Rouleau et al., 2004; Green 
48 
Ch 4 Results and Discussion 
and Leeuwenburgh, 2002). This present study provides the first evidence of the 
potential effects of TPO against DOX-induced cardiac damage in the in vitro models 
of H9C2 cell line and primary neonatal rat cardiomyocytes. 
The observed cardiotoxic effects of DOX on H9C2 are consistent with previous 
reports (bou-El-Hassan et aL, 2003; Kim et al., 2003). The formation of dark blue 
formazan from pale yellow tetrazolium dye MTT by mitochondrial dehydogenase was 
used to assess mitochondrial redox potential and cell viability (bou El Hassan et al.’ 
2003). Green and Leeuwenburgh (2002) reported that 10 jiM of DOX 5 |ag/mL)，a 
similar level in patients' plasma after pharmaceutical use of DOX, resulted in 
_^一 significant mitochondrial dysfunction with significant decrease in cell viability, as 
assessed by the MTT assay. Pretreatment of TPO increased cell viability of 
DOX-treated H9C2 cells. This result was comparable to that of dexrazoxane, the 
clinically approved cardioprotective drug. 
In the study of primary rat cardiomyocytes, we investigated the beating rates of 
the ventricular cardiomyocytes as the index of their viability and functioning, and our 
result showed that TPO partially recovered the beating rate of DOX-treated 
cardiomyocytes. A previous report addressed that 10-16 % of cardiomyocytes was still 
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viable even they completely stopped beating (Cini et al., 1991)，indicating that the 
high energy demanding processes, such as beating, stops before the cardiomyocyte 
completely die. The termination of the high energy demanding processes might be due 
to the reduction of cellular ATP level by DOX (Imondi et al, 1996). The improved 
contractile activity of DOX-treated cardiomyocytes might be due to the anti-apoptotic 
function of TPO. 
The protective effect of TPO on cell survival of H9C2 cells and beating rates of 
cardiomyocytes were comparable to that of dexrazoxane at a recommended dose of 10 
times of DOX (Swain and Vici, 2004). Dexrazoxane is clinically approved for the 
prophylaxis of DOX toxicity. However, dexrazoxane could not provide complete 
protection. Previous studies on breast cancer patients treated with dexrazoxane 
showed that 7-14 % of them experienced cardiac complications (Hochster et al” 1992; 
Bjelogrlic et al., 2005). A higher dose of dexrazoxane is associated with increased risk 
of neutropenia and myelotoxicity in cancer patients. (Olson et al., 2003). In addition, 
dexrazoxane is also toxic to haematopoietic cells and may result in chemical phlebitis 
(Rosenoffer aL, 1975; Pacher et al., 2002; Liu et aL, 2004). 
In the present study, we illustrated that TPO increased H9C2 cell viability and 
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Figure 4.1 Viability of H9C2 cells by MTT assay. 
H9C2 cells were pretreated with or without TPO (5, 10，50, 100 ng/mL, overnight), or 
dexrazoxane (DEX; 50 |^g/mL, 30 minutes) before DOX administration (5 |ig/mL) for 
24 hours, and cell viability was determined by MTT assay. Results are expressed as 
percentage of viable cells compared to untreated Control as mean 土 SD. Pretreatment 
with TPO (50 ng/mL and 100 ng/mL) significantly increased cell viability 
(Mann-Whitney test, n = 4; * p = 0.010 and * p = 0.016 respectively). 
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Figure 4.2 Beating rates of primary cardiomyocytes in culture. 
Primary neonatal rat cardiomyocytes were incubated with or without DOX (1 )LIM) or 
pretreatment with dexrazoxane (5.8 i^ g/mL) or TPO (50 and 100 ng/mL). Results are 
expressed as mean 土 SD of the beating rates of the same colony in response to 
treatment. DOX significantly reduced the beating rates of primary cardiomyocytes 
(Mann-Whitney test, # p < 0.001，n = 10) compared with Control cultures. 
Pre-incubation with TPO at 50 ng/mL, 100 ng/mL or dexrazoxane at 5.8 )Lig/mL 
significantly increased the beating rats of DOX-treated cardiomyocytes at 48 hours (* 
p = 0.002, * p = 0.002 and * p = 0.001 respectively). The light micrograph 
demonstrating a beating cell colony is shown on the right panel. 
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C H A P T E R 5 
E f f e c t s of T h r o m b o p o i e t i n on the 
Protection against DOX-induced Heart 
Injury In Vivo 
SECTION 5.1 Results 
5.1.1 General Observations and Survival 
There was a significant difference in body weights of DOX-treated mice and 
Control mice at Day 5 (18.8 土 2.1 g，n = 14 vs. 24.0 土 1.4 g，n = 13) (p < 0.001). 
In the DOX+TPO group, no increase in body weights was observed (18.5 土 1.7 g，n 
二 13). Treatment with TPO alone had similar body weights (23.3 土 0.5 g, n = 8) 
with the Control group. We observed similar heart weight:body weight ratio among 
the 4 groups. Heart weight: body weight ratio of DOX-treated mice did not differ 
from Control mice (5.9 土 0.9 mg/g vs. 5.9 土 0.7mg/g). No difference in dry weight 
of the hearts between treatment groups on Day 5. 
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In all series of experiment, consistently 100 % of control and TPO alone treated 
mice survived, whereas only 66.7 % of DOX-treated mice survived (n = 39) at Day 
5. A trend in increased survival rates of DOX+TPO-treated mice (n = 36) was 
observed when compared with DOX-treated mice (p = 0.097). 
In an independent and prolonged experiment, mice were not subjected to daily 
manipulation and echocardiography monitoring. The survival rates of mice (n = 20, 
each group) from each group are shown in Figure 5.1. Mortality was first observed 
at Day 4 and only 20 % of DOX-treated mice survived at Day 8. The survival rate of 
DOX+TPO-treated mice was increased to 50 % (p = 0.018). 
5.1.2 Blood Cell Counts 
Blood cell counts conducted at Baseline (Day -1) revealed no significant 
difference among 4 groups of mice. (Table 5.1). At Day 5，DOX-treated mice 
showed significant reductions in RBC, WBC and platelet counts when compared 
with those counted at baseline of the same animals (all * p < 0.01 for all blood cell 
counts). Platelets counts of DOX+TPO-treated group and TPO alone group were 
increased at Day 5 (p < 0.001 and * p = 0.008，respectively). 
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5.1.3 Cardiac Functions by Echocardiography 
Echocardiographic assessments of heart function parameters for all groups of 
mice are shown in Figure 5.2 and Table 5.2. There were no significance difference of 
heart rate (HR), fractional shortening (FS) and cardiac output (CO) between 4 
groups of mice at baseline (Day -1). HR of DOX-treated mice (n = 14) decreased 
progressively in comparison of the Control mice (n = 13) from baseline (Day -1) to 
Day 5 after DOX-treatment (Figure 5.2, quadratic trend p = 0.038)，whereas 
increased heart rates were observed in DOX+TPO-treated mice (n = 13，p = 0.001). 
Five days after DOX treatment, FS was significantly decreased in DOX-treated 
_ group, compared with that of baseline (Day -1) (* p < 0.001). In the DOX+TPO 
group, reduction in FS was observed (Day -1 vs. Day 5, p = 0.006)，but with a 
significantly higher level than that of DOX-treated group at Day 5 (# p < 0.001, 
Table 5.2). In both DOX-treated and DOX+TPO-treated mice, there were significant 
decrease in left ventricular end-diastolic dimension (LVEDD) at Day 5 (both * p < 
0.001) when compared with those at baseline (Day -1)，while there was no 
difference in left ventricular end-systolic dimension (LVESD) between the four 
treatment groups. DOX treatment decreased CO in both DOX-treated and 
DOX+TPO-treated groups at Day 5 (both * p < 0.001). Improved CO were observed 
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in DOX+TPO-treated groups at Day 5 (# p = 0.008). Administration ofTPO alone 
had no effect on cardiac functions. Representative M-mode echocardiograms of 4 
treatment groups at Day 5 are shown in Figure 5.3. 
5.1.4 Gross Anatomic Changes and Pathology of the Myocardium 
At time of sacrifice, smaller heart size was observed in DOX-treated mice, 
compared with untreated Control mice. No pleural effusion, lung oedema or ascites 
was observed among treatment groups. Transverse sections of hearts stained with 
hematoxylin-eosin (Figure 5.4) revealed the myocardial pathology associated with 
DOX treatment, including myofibrillar loss and cytoplasmic vacuolization. Due to 
extensive postmortem alternations, mice that died before Day 5 were only dissected 
for gross anatomic changes without examining the histopathology of the heart. In the 
Control group, no cardiomyocyte alternations were observed. Significant increased 
lesion score was observed in DOX-treated group, compared to Control group (* p < 
0.001，Table 5.3). Cardiomyocyte alternations were significantly less severe in 
DOX+TPO-treated group than DOX-treated group (# p < 0.001). TPO alone group 
showed normal myocardial morphology. 
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SECTION 5.2 Discussion 
Acute cardiac dysfunction has been demonstrated in a well established murine 
model of DOX-induced cardiotioxicity. (Delia et al, 1999; Childs et al., 2002; Liu 
et al., 2002; Olson et al, 2003; Nozaki et al, 2004). In the present study, we 
\ 
administered a single dose of DOX at 20 mg/Kg, i.p.，a dosage as in most of other 
studies. Our data on DOX-induced cardiotoxicity are in agreement with previous 
reports showing reduced heart weight, unaltered heart/body weight ratio, low blood 
cell count, lesions of myocyte, apoptotic cell death, cardiac dysfunction and animal 
mortality (van, V et al., 1990; Weinstein et al, 2000; Mihm et al, 2001).The present 
study showed that the administration of TPO significantly reduced DOX-induced 
cardiotoxicity in mice. 
In this study, the assessment of cardiac functions 5 days after a single dose of 
DOX was accomplished by the use of M-mode Doppler method. This method is 
accurate and non-invasive, and is easier to perform than telemetric 
electrocardiogram (ECG) recording. However, information about 
electrophysiological change of the heart could not be obtained. Moreover, 5 days 
after DOX administration was chosen as the time point for functional and 
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histological assessments because this time point is larger than five times of the 
elimination half lives of DOX from both plasma and cardiac muscles in mice. 
Therefore, DOX was not present in the blood and heart tissues of mice at the time of 
assessments (Mihm et al., 2001; Liu et aL, 2002; Liu et aL, 2004; Liu et al.’ 2005; 
Matoba et al., 2005). 
Our results demonstrated that DOX administration caused a gradual decrease in 
heart rates, reduced heart size and decreased fractional shortening and cardiac output, 
which are consistent with previous studies of DOX-induced acute cardiotoxicity 
(Fanucchi et al., 1997; Vadhan-Raj et al., 2002; Vadhan-Raj et al” 2003; Angiolillo 
et al., 2005). These findings are in contrast to clinical observations on chronic 
cardiomyopathy developed by repeated administrations of small doses of DOX over 
a period of time. We speculate that the very acute DOX cardiotoxicity, at dose 20 
mg/Kg, did not allow time for the myocytes to compensate. The mechanism of 
decreased heart rate in DOX-treated mice with acute cardiac decompensation 
remains unclear and warrants further study. 
Animal mortality and depressed cardiac performance might not be entirely 
contributed to the acute toxicity induced by DOX in mice. Reductions in heart 
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weight and body weight might be resulted from severe anorexia, poor oral intake 
and dehydration caused by the cytotoxic effects of DOX to other organs as well as 
the heart. Moreover, similar heart weight:body weight ratio between treatment 
groups suggested that DOX attenuated the overall body growth in DOX-treated 
mice . 
It has been known that TPO promotes haematopoietic stem cells, particularly 
the megakaryocytic lineage. In the present study, recovery of white blood cell and 
platelet counts were observed in mice receiving TPO treatment. TPO has been 
showed to exert beneficial effects on cancer patients in different clinical trials for 
treating chemotherapy-induced severe thrombocytopenia (Shibuya et al., 1998). 
- 一 -
Vadhan-Raj et al. (2003) suggested that the timing of TPO administration (one dose 
before and one after chemotherapy) played a vital role in optimizing the effects on 
platelet recovery in cohorts of sarcoma patients. TPO application in reducing 
cardiotoxicity might therefore be beneficial to patients receiving chemotherapy and 
dexrazoxane by ameliorating neutropenia and thrombocytopenia. 
I 
In summary, administration of TPO, at a relatively low dose of TPO 
administration (12.5 i^ ig/Kg) (Cossarizza et al” 1993; Reers et al, 1995) for 3 
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alternate days, improved the survival rates of DOX-treated mice and attenuated the 
cardiac toxic effects of DOX-induced functional and morphological alternations in 
the mouse hearts. 
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Figure 5.1 Cumulative survival of experimental animals. 
Kaplan-Meier survival curves showed significant increase of survival rate in 
DOX+TPO group then DOX group, compared by Log Rank test (p = 0.018). No 
mortality was observed in the Control group and TPO group. 
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Figure 5.2 Daily heart beating rates of experimental animals. 
There was no significant difference in heart rates of mice beween the 4 treatment 
groups at baseline. Significant difference in heart rates of DOX-treated mice (n = 14) 
was observed when compared with the Control group (n = 13, quadratic trend p = 
0.038) or the DOX + TPO-treated group (n = 13，p = 0.001), analyzed by the 
Multilevel modeling and Likelihood Ratio test. TPO treatment did not affect the trend 
of heart rates (n = 8). 
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Figure 5.3 Representative echocardiograms of experimental animals. 
DOX administration (20 mg/Kg, i.p.) caused significant left ventricular dysfunction as 
indicated by two-dimensional M-mode echocardiographic analysis of wall motion at 
Day 5, when compared with the Control. DOX+TPO-treated mice showed significant 
improvement in cardiac functions. No effect on cardiac functions was observed in 
TPO only group. 
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Figure 5.4 Hisopathology of myocardium from experimental animals. 
Representative photomicrographs of left ventricles from mice in the indicated groups 
are shown (hematoxylin and eosin staining, scale bar = 20 |im). (A) Control mice and 
(B) TPO mice showed normal myocardium morphology. (C) DOX-treated mice 
showed increased cytoplasmic vacuolization and myofibrillar loss. (D) 
DOX+TPO-treated mice showed reduced myocardial lesions. 
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Table 5.1 Blood cell counts at baseline (Day -1) and Day 5. 
WBC (x10 /^L) RBC (x10^ /^L) Platelet (x10 /^L) 
, 一 � D a y - 1 7.5±1.5 8.7±0.8 934±55 
Control n=13 
Day 5 7.6±1.2 8.9±0.9 964±81 
, ^ � D a y - 1 8.3±1.8 * 9.7±1.2 * 916±10 * 
DOX n=14 
Day 5 4.7±1.4 9.3±1.2 833±121 
, � D a y - 1 7.9±1.1 9.7±1.2 967±102 * 
DOX+TPO n=13 
Day 5 6.0±2.3 9.3±1.1 1135±108 
, � � D a y - 1 7.9±1.3 8.9±1.3 944±59 * 
TPO (n=8) 
Day 5 8.2±1.3 9.1±0.9 1330±124 
Results are expressed as means 土 SD. Data were analysed by comparing values at 
baseline (Day -1) and Day 5. No significant differences of all parameters were 
observed between treatment groups at baseline. Abbreviations are as defined in the 
text. 
* p < 0.01 (Day-1 vs. Day 5 in the same treatment group; Wilcoxon Signed Rank test) 
#p < 0.01 (DOX group vs. DOX+TPO group on Day 5; Mann-Whitney test). 
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Table 5.2 Echocardiographic measurements at baseline (Day -1) and Day 5. 
Fractional Shortening Cardiac Output LVEDD LVESD 
(FS’ ％) (CO, mL/min) (mm) (mm) 
D a y - 1 58.1±3.3 9.6士3.0 2.84±0.29 1.18 土 0.15 
Control (n=13) 
Day 5 59.6±3.9 10.6±2.5 2.86士0.23 1.15±0.12 
D a y - 1 57.9±5.2 * 10.3±2.2 * 2.83土0.03 * 1.20土0.19 
D O X (n=14) 
Day 5 44.2±7.1 3.9±2.0 2.21±0.23 1.21 土0.15 
D a y - 1 57.5±4.9 * 11.7土3.6* 2.87土0.28 * 1.22士0.11 
DOX+TPO (n=13) 
Day 5 53.7土6.4 # 5.7土2.1 # 2.34土0.19 1.14±0.17 
D a y - 1 56.7±5.3 11.6±1.4 2.81 士 0.15 1.22±0.17 
TPO (n=8) 
Day 5 57.6士4.9 11.9士 1.8 2.84士0.15 1.20土0.12 
Results are expressed as means 士 SD. Data were compared on the differences 
between values at baseline (Day -1) and Day 5. No significant differences of all 
parameters were observed between treatment groups at baseline. Abbreviations are 
as defined in the text. 
* p < 0.01 (Day-1 vs. Day 5 in the same treatment group; Wilcoxon Signed Rank test) 
# p < 0.01 (DOX group vs. DOX+TPO group on Day 5; Mann-Whitney test). 
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Table 5.3 Cardiomyopathy scores of experimental animals. 
Cardiomyopathy Score 
Group 
0 1 1.5 2 2.5 3 
Control (n=13) 13 0 0 0 0 0 
DOX* (n=14) 0 0 1 1 3 9 
DOX+TPO # (n=13) 0 0 4 7 2 0 
TPO (n=8) 8 0 0 0 0 0 
The severity of cardiac damage was graded from 0 to 3 according to the percentage 
of myocyte vacuolization and myofibrillar loss. The Kruskal-Wallis Ranking test 
showed significant differences between treatment groups (p < 0.001). The 
cardiomyopathy score was significantly increased in DOX-treated mice compared 
with Control mice (Mann-Whitney test, * p < 0.0001)，and was reduced in 
DOX+TPO-treated animals (#p = 0.002) compared with the DOX group. 
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C H A P T E R 6 
Effects of Thrombopoietin on Apoptosis 
and Mitochondr ia l Integrity of H9C2 
Cell Line and Apoptosis In Vivo 
SECTION 6.1 Results 
6.1.1 Determination of Externalized Phosphatidylserine 
Early apoptotic cells (Annexin V+ PI", R2) were increased after exposure to 
DOX (0.58 ng/mL) for 24 hours (7.16 %，* p = 0.016; n = 7)，as assessed by 
Annexin V/ PI staining (Figure 6.1). Total dead cells, including apoptotic cells and 
necrotic cells (Annexin V+ PI" and Annexin V+ PI+ respectively; i.e. R1+R2) were 
also elevated to 19.07 %, as compared to the control. Pre-treatment of cells with 
TPO (100 ng/mL) for 2 hours decreased the number of apoptotic cells and total dead 
cells to 3.52 % and 7.81 % respectively near to the control level (# p = 0.016, n = 7). 
TPO alone did not affect H9C2 cells on apoptosis. 
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6.1.2 Determination of Active Caspase-3 Activity 
Expression of active caspase-3, a downstream effector protein of apoptosis, was 
determined to further confirm the induction of apoptosis in DOX-treated H9C2 cells 
as another evidence of apoptosis. Caspase-3 was significantly activated in cells 
treated with 0.58 |ig/mL of DOX for 24 hours. DOX significantly elevated the 
population of cells expressing caspase-3 (* p = 0.016) and the mean fluorescence 
intensity of expression, as compared to the control (p = 0.016，Figure 6.2). TPO at 
100 ng/mL significantly reduced the up-regulation of active caspase-3 from 79.24 % 
(DOX group) to 38.47 % (DOX+TPO group) of cell population (# p = 0.016)，and 
49.76 % to 22.23 % of the relative mean fluorescence intensity (p = 0.016，Figure 
一 一 
6.2). However, DOX-induced caspase-3 activation was not totally recovered by TPO 
treatment. TPO alone administration did not show any effect on the expression of 
active caspase-3. 
6.1.3 Assessment of Mitochondrial Membrane Potential 
Mitochondrial dysfunction has been demonstrated to play a key role in 
apoptosis. Intact mitochondria have highly negative mitochondrial membrane 
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potential (A平m). JC-1 is a lipophilic cation fluorescent probe that is actively and 
reversibly accumulated into mitochondria, due to the negative (internal) potential 
across the inner mitochondrial membrane (Narula et aL, 1998). The accumulation 
of JC-1 forms JC-1 aggregates with a shift in emission from green fluorescence 
(monomeric form) to red/orange fluorescence. Significant differences on the JC-1 
status were observed among 4 treatment groups (Friedman test p < 0.002). The 
addition of DOX increased the cell population in R1 and R2 containing JC-1 
monomers with green fluorescence, showing a trend in loss of A平m when compared 
to the Control (17.9 土 9.5 % vs. 7.5 土 3.6 %, p = 0.028，n = 6，Figure 6.3). R1 
represents a population at the transition form JC-1 aggregates to monomers (early 
apoptosis) and R2 represents a population of cells containing depolarized 
mitochondrial membrane and JC-1 monomers (late apoptosis). Pre-treatment with 
TPO for 2 hours reduced the apoptotic cell population to 11.3 土 7.2 % (p = 0.028) 
at the concentration of 100 ng/mL. TPO alone did not significantly alter A中m status. 
Similar trends were observed when independently analyzing the population of cells 
in R1 and R2 among treatment groups. 
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6.1.4 Determination of Apoptosis by TUNEL assay 
A significant increase in the number of apoptotic nuclei was observed in heart 
sections after DOX treatment, as assessed by the semi-quantitative TUNEL assay (* 
p < 0.001，n = 5，Figure 6.4). In DOX-treated mice, a significant increase in numbers 
of TUNEL-positive apoptotic nuclei was demonstrated (* p < 0.001，n = 5), 
compared with control mice. Number of apoptotic nuclei was significantly reduced 
in DOX+TPO-treated mice (# p = 0.019). TPO alone did not show any effect on 
cardiomyocyte apoptosis. 
SECTION 6.2 Discussion 
Apoptosis has been shown to contribute to the loss of cardiomyocytes in 
myocardial dysfunction and the development of congestive heart failure. (Leri et al., 
1998; Yue et al., 2000; Condorelli et al” 2001; Pacher et al., 2002; Liu et al.’ 2004) 
Several reports illustrated that DOX-induced cardiotoxicity involves cardiomyocytes 
apoptosis. (Wang et al.’ 1998; Kotamraju et al” 2000; Yamanaka et al., 2003; 
Spallarossa et al” 2004; Khan et al., 2006). We demonstrated that DOX-treated 
H9C2 cells undergo apoptosis, as evidenced by the increase in Annexin V staining 
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and expression of active caspase-3. Our results are consistent with the results 
reported by others, who demonstrated DOX-induced apoptosis and suggested that 
this is associated with the activation of Bax and caspase-3 (Khan et al.’ 2006). 
Pretreatment with TPO at 100 ng/mL, doses commonly reported as effective in 
promoting haematopoietic cells in culture, has significantly reduced DOX-induced 
Annexin V staining and caspase-3 activation in H9C2 cells. 
Caspase cascade is activated in the failing myocardium (Wang et al” 2004). 
Previous study on DOX-induced apoptosis demonstrated that activation of caspase-3 
preceded other apoptotic signals such as p53 in cardiac cells (Kang and Izumo, 
2000). Caspase-3, a key effector enzyme, activates downstream caspases to execute 
the apoptotic signals for final morphological and biochemical alternations of cell 
death (Moretti et al., 2002; Lou et aL, 2005). Apart from inducing apoptosis, active 
caspase-3 has been reported to directly cleave three components of the cardiac 
myofibrillar proteins, including a-actin, a-actinin and troponin T (TnT). The 
cleavage of the myocardium results in reduction of cardiac function, myocardial 
disruption and cytoskeleton-sarcomeric network disorganization. Consequently, both 
DOX-induced apoptosis and cardiac dysfunction in the development of 
cardiomyopathy may be mediated by caspase activation (Ly et aL, 2003). 
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Mitochondrial dysfunction has been suggested to play an important role in the 
induction of apoptosis (Chae et al., 2005; Kim et al., 2005). Previous studies 
reported that DOX decrease mitochondrial membrane potential in cardiac muscle 
cells (Chae et al., 2005; Kim et al., 2005). However, we did not show statistically 
significant result on DOX-induced collapse of mitochondrial membrane potential in 
H9C2 cells. This might be due to the different conditions and protocols in different 
experiments. In our experimental setting, H9C2 cells were treated with DOX for 2 
hours, while in others studies H9C2 cells were treated for 24 hours (Kroemer et al., 
1998). The shorter incubation time of DOX might cause a partial reduction of 
mitochondrial membrane potential without completely disrupting the membrane 
potential (Liu et al, 2005). Therefore, pre-treatment of TPO did not show 
— -
cardioprotection by preserving the dissipation of mitochondrial membrane potential 
induced by DOX. 
DOX-induced apoptosis was further confirmed in the in vivo model. 
DOX-treated mice showed significantly increased no. of apoptotic nuclei after 3 
days of DOX administration, comparable with previous report (Latronico et al., 
2004). Pre-treatment of TPO reduced no. of apoptotic nuclei. From the results on 
H9C2 cells and mouse hearts, we suggested that the protective effects of TPO 
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against DOX-induced apoptosis were possibly mediated by anti-apoptosis. 
The Akt pathway has been known to have protection on cardiomyocyte survival 
(Majka et al., 2002; Siguijonsson et al., 2004). TPO has been shown to have 
anti-apoptotic effects on haematopoietic stem cells and megakaryocytes mediated by 
the Akt pro-survival pathway. We suggest further investigating the role of Akt 
pro-survival pathway in the mechanism of TPO against DOX-induced cardiac injury. 
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Figure 6.1 Annexin V staining of H9C2 cells. 
H9C2 cells were pre-treated with or without TPO (100 ng/mL) for 2 hours before the 
addition of DOX for 24 hours, and apoptosis was determined by Annexin V staining. 
Upper panel showed the representative dot-plots of Annexin V / PI staining among 4 
treatment groups. Region R2 consisted of early apoptotic cells with high levels of 
Annexin V but low levels of PL Region R1 included late-phase apoptotic or necrotic 
cells with high levels of both Annexin V binding and PI penetration. DOX treatment 
z increased early apoptoic cells (R2) and total dead cells (R1+R2) (n = 7). Cell 
populations in region R2 and R1+R2 were decreased significantly after pre-incubation 
with TPO before DOX adminstration. TPO alone did not affect H9C2 cells on 
apoptosis (lower panel). (Wilcoxon Signed Rank test; * p = 0.016, DOX vs. Control 
group; # p 二 0.016，DOX + TPO vs. DOX group). 
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Figure 6.2 Active caspase-3 expression in H9C2 cells. 
H9C2 cells pre-incubated with or without TPO (100 ng/mL) for 2 hours before the 
addition of DOX (0.58 jig/mL) for another 24 hours, and assayed by flow cytometry 
for the expression of active caspase-3. A representative flow cytometric histogram 
(upper panel) showed a higher level of active caspase-3 expression in DOX-treated 
cells, compared with that of the Control untreated cells, as demonstrated by their 
mean fluorescence channels (FL-2). Active caspase-3 expression was significantly 
decreased by pre-treatment with TPO. TPO only did not show any effect on caspase-3 
expression (lower panel). (Wilcoxon Signed Rank test, n = 7; * p = 0.016，DOX vs. 
Control group; # p = 0.016，DOX + TPO vs. DOX group.) 
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Figure 6.3 Mitochondrial membrane potential (ATm) changes in H9C2 cells. 
H9C2 cells were pre-treated with TPO (100 ng/mL) for 2 hours before the addtion of 
DOX (0.58 |_ig/mL) for another 2 hours. Cells were washed to removed DOX and 
incubated with TPO for another 22 hours, and assessed for JC-1 by flow cytometry. 
Representative flow cytometric dot-plots demonstrated that DOX-treated H9C2 cells 
exhibited a trend of increased JC-1 monomers (green fluorescence in FL-1, R1+R2). 
Pre-treatment with TPO decreased the damage (n = 6; both p = 0.028; Wilcoxon 
Signed Rank test). TPO alone did not significantly altered A^m status. Results on 
independently analyzing the early (region Rl , cells at transition from JC-1 aggregates 
o monomers) and late (region R2, cells consisting of JC-1 monomers) apoptotic 
populations were observed with similar trends. 
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Figure 6.4 Myocardium apoptosis in vivo by TUNEL assay. 
Representative myocardial sections (upper panel) from mice treated with DOX (A) 
and DOX + TPO (B) showed TUNEL-stained positive apoptotic nuclei (green 
fluorescence; x 400 magnification). Lower panel showed the no. of apoptotic nuclei in 
the 4 treatment groups (n = 5, six sections counted per heart). DOX treatment 
'- significantly increased the no. of apoptotic nuclei when compared with the Control 
group (Mann-Whitney test, * p < 0.001). Reduced no. of apoptotic nuclei was 
observed in DOX+TPO-treated mice, compared with the DOX group (# p = 0.019). 
TPO alone had no effect on cardiomyocyte apoptosis. 
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C H A P T E R 7 
General Discussion and Conclusion 
Reports regarding TPO as a cardioprotective agent against DOX-induced 
cardiotoxicity have not yet been documented. Our study provides the first evidence on 
the potential protective effects of TPO against cardiotoxicity induced by DOX. 
We demonstrated that TPO protected DOX-induced cardiac injury in the in vitro 
models. TPO increased cell viability of DOX-treated H9C2 cells and improved the 
contractile function of DOX-treated primary neonatal rat cardiomyocytes. However, 
we did not test whether TPO would interfere with the anti-tumour effect of DOX in 
cancer cell line. 
We also established an in vivo mouse model of DOX-induced cardiotoxicity and 
illustrated the protective effects of TPO in this model. Effects of TPO were confirmed 
by the improvement of survival rates of DOX-treated mice and reduction in cardiac 
toxic effects of DOX as indicated by cardiomyopathy score and functional parameters. 
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We employed the acute model in this study, but it is quite different from 
cardiomyopathy developed in human in the clinical situation. We suggest further 
investigating protective effect of TPO against chronic rat model of DOX-induced 
cardiotoxicity. 
The mechanism of TPO was possibly mediated by the anti-apoptotic activity 
against DOX-induced cardiac damage, as demonstrated by assays of annexin V，active 
caspase-3 and mitochondrial membrane potential (A^m) in H9C2 cells, and TUNEL 
assay in mouse hearts. 
In our study, the use of TPO showed significant effects on the cardioprotection 
against DOX treatment in both in vitro and in vivo models. However, TPO did not 
fully protect the cardiomyocytes from injury when compared to the control group. We 
therefore propose to evaluate a potential combination therapy with TPO and other 
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